Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of AZD6750 With or Without Rilvegostomig in Advanced or Metastatic Solid Tumors
jRCT2031250512Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of AZD6750 in melanoma, non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma (cSCC) and 7 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD6750 (monotherapy and combination) and Preliminary anti-tumor activity of AZD6750 + rilvegostomig. Started Dec 2025; status: recruiting.
02
Drugs
AZD6750
03
Conditions
melanomanon-small cell lung cancer (NSCLC)cutaneous squamous cell carcinoma (cSCC)renal cell carcinoma (RCC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on jRCT2031250512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250512.